Suzetrigine vs Norco-PostOp Mohs Pain

NCT07575230 | Enrolling By Invitation Phase 4 FDA Drug

• 1 other identifier: 025-413
• Study Type: interventional
• Target: 75
• Locations: 1 country
• Sites: 1

Brief Summary

To compare suzetrigine versus hydrocodone/acetaminophen for postoperative pain control following dermatologic surgery.

Conditions

Cutaneous Tumors; Mohs Micrographic Surgery

Outcome Measures

Primary Outcomes (1)

• Change in need for opioid medication for pain management after Mohs micrographic surgery

  Change in mean visual analog scale (VAS; 0-10) pain scores at 24 and 48 hours after surgery with a minimal change in pain score of 1.0 points.

  48hours post surgery

Secondary Outcomes (3)

• Patient-reported adequacy of pain control

  48hours post surgery

• Rescue pain management use

  48hours post surgery

• Adverse Events

  3 days after surgery

Study Arms (2)

Standard of Care

ACTIVE COMPARATOR

Participants will receive the standard of care drug Norco (a medicine that combines hydrocodone and acetaminophen).

Drug: Norco 5Mg-325Mg Tablet

Control

ACTIVE COMPARATOR

Participants will receive the control drug, Suzetrigine.

Drug: Suzetrigine

Interventions

Norco 5Mg-325Mg Tablet DRUG

Standard of care drug

Standard of Care

Suzetrigine DRUG

Control Drug

Control

Eligibility Criteria

• Age: 18 Years - 89 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• adults between the age of 18-89
• individuals who have a cutaneous tumor treated by MMS

You may not qualify if:

• individuals younger than 18 and older than 89
• individuals taking medications that interact with the CYP3A (Cytochrome P450 3A) pathway
• individuals with liver disease

Sponsors & Collaborators

• Baylor Research Institute: lead

Study Sites (1)

Baylor University Medical Center

Dallas, Texas, 75246, United States

Location

Related Publications (2)

• Ad Hoc Task Force; Connolly SM, Baker DR, Coldiron BM, Fazio MJ, Storrs PA, Vidimos AT, Zalla MJ, Brewer JD, Smith Begolka W; Ratings Panel; Berger TG, Bigby M, Bolognia JL, Brodland DG, Collins S, Cronin TA Jr, Dahl MV, Grant-Kels JM, Hanke CW, Hruza GJ, James WD, Lober CW, McBurney EI, Norton SA, Roenigk RK, Wheeland RG, Wisco OJ. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol. 2012 Oct;67(4):531-50. doi: 10.1016/j.jaad.2012.06.009. Epub 2012 Sep 5. Erratum in: J Am Acad Dermatol. 2015 Apr;72(4):748. PMID: 22959232.

  BACKGROUND

• Phillips, Shay, et al.

  BACKGROUND

MeSH Terms

Conditions

Skin Neoplasms

Interventions

oxycodone-acetaminophen

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Stan Tolkachjov, MD

  Baylor Medical University Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Participants are randomized into one of two group: interventional group and control group

Study Record Dates

• First Submitted: May 4, 2026
• First Posted: May 8, 2026
• Study Start: November 3, 2025
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): December 1, 2027
• Last Updated: May 8, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)